|
|
| | 5H-Imidazo[2,1-b][1,3]oxazine, 6,7-dihydro-2-nitro-6-[4-(trifluoromethoxy)phenoxy]- Basic information |
| | 5H-Imidazo[2,1-b][1,3]oxazine, 6,7-dihydro-2-nitro-6-[4-(trifluoromethoxy)phenoxy]- Chemical Properties |
| Melting point | 151-153 °C | | Boiling point | 463.9±55.0 °C(Predicted) | | density | 1.63±0.1 g/cm3(Predicted) | | pka | -0.79±0.40(Predicted) |
| | 5H-Imidazo[2,1-b][1,3]oxazine, 6,7-dihydro-2-nitro-6-[4-(trifluoromethoxy)phenoxy]- Usage And Synthesis |
| Uses | (Rac)-DNDI-8219 is an antituberculosis compound with potent anti-leishmanial activity. (Rac)-DNDI-8219 demonstrated superior efficacy in the Leishmania donovani mouse model. (Rac)-DNDI-8219 showed promising activity in the Leishmania infantum hamster model. (Rac)-DNDI-8219 candidate compound R-6 provided excellent oral efficacy in the same hamster model[1]. | | References | [1] Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis DOI:10.1021/acs.jmedchem.7b01581 |
| | 5H-Imidazo[2,1-b][1,3]oxazine, 6,7-dihydro-2-nitro-6-[4-(trifluoromethoxy)phenoxy]- Preparation Products And Raw materials |
|